Effekter av 5-Metyltetrahydrofolsyre-tilskudd på mors helse og ett-karbonmetabolisme under amming (OCMS)
Effekter av 5-MetylTetrahydrofolsyre-tilskudd på mors helse og ettkarbonmetabolisme under amming
This double-blind, randomized, placebo-controlled parallel trial evaluates the effects of maternal 5-methyltetrahydrofolate (5-MTHF) supplementation during breastfeeding. Thirty-six lactating mother-infant dyads will be randomized (1:1) to receive 5-MTHF or placebo for 6 weeks, stratified by infant sex and mode of delivery. Tolerability and adverse events will be monitored.
Pre- and post-intervention assessments include breast milk one-carbon metabolites and oligosaccharides; maternal plasma one-carbon metabolites and metabolic health markers. Maternal mental health will be evaluated using the SCL-90-R questionnaire. A follow-up visit at 4 months will reassess infant anthropometry and microbiome outcomes.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Carles Lerin, PhD
- Telefonnummer: (+34) 93 600 97 51
- E-post: carles.lerin@sjd.es
Studer Kontakt Backup
- Navn: Marta Ramon Krauel, MD PhD
- Telefonnummer: Ext. 71263 (+34) 93 280 40 00
- E-post: marta.ramon@sjd.es
Studiesteder
-
-
Barcelona
-
Barcelona, Barcelona, Spania, 08950
- Rekruttering
- Hospital Sant Joan de Deu
-
Ta kontakt med:
- Carles Lerin, PhD
- Telefonnummer: (+34) 93 600 97 51
- E-post: carles.lerin@sjd.es
-
Barcelona, Barcelona, Spania, 08950
- Har ikke rekruttert ennå
- Hospital Sant Joan de Déu
-
Ta kontakt med:
- Carles Lerin, PhD
- Telefonnummer: 936009751 Spain
- E-post: carles.lerin@sjd.es
-
Ta kontakt med:
- Carles Lerin
- Telefonnummer: 601106790 Spain
- E-post: carleslerin@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Maternal age between 18 and 42 years
- Gestational age at birth ≥ 37 weeks.
- Exclusive breastfeeding at enrollment.
- Infant age 0-1 months
Exclusion Criteria:
- Multiple pregnancy
- Presence of disease or malformations in the infant.
- Weight-Standard Deviation Score < -1 at enrollment.
- Use of folate-containing multivitamin supplements during breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Placebo |
Matching placebo administered daily for 6 weeks during lactation. |
|
Eksperimentell: 5-MTHF Supplementation
Dietary Supplement (5-MTHF) |
Oral supplementation with 5-MTHF (800 µg) administered daily for 6 weeks during lactation. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse Events
Tidsramme: Baseline, 6 weeks, 4 months
|
Treatment safety and tolerability will be evaluated by assessing differences in the incidence of potential adverse events between groups, focusing on gastrointestinal symptoms. |
Baseline, 6 weeks, 4 months
|
|
Change in breast milk 5-MTHF concentration
Tidsramme: Baseline, 6 weeks
|
Change in breast milk 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma 5-MTHF concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal plasma 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in breast milk one-carbon metabolite concentration
Tidsramme: Baseline, 6 weeks
|
Change in breast milk one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in plasma one-carbon metabolite concentration
Tidsramme: Baseline, 6 weeks
|
Change in plasma one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in Human Milk Oligosaccharide (HMO) concentration
Tidsramme: Baseline, 6 weeks
|
Change in HMO concentrations between Baseline and 6 weeks |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Glucose Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal blood glucose levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Glycated Hemoglobin (HbA1c) Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal blood glycated hemoglobin (HbA1c) between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Insulin Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal blood insulin levels between Baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Triglyceride (TAG) Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal blood triglyceride (TAG) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Total Cholesterol Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal blood total Cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood LDL Cholesterol Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal low-density lipoprotein (LDL) cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood HDL Cholesterol Concentration
Tidsramme: Baseline, 6 weeks
|
Change in maternal high-density lipoprotein (HDL) cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Alanine Aminotransferase (ALT) Levels
Tidsramme: Baseline, 6 weeks
|
Change in maternal alanine aminotransferase (ALT) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Aspartate Aminotransferase (AST) Levels
Tidsramme: Baseline, 6 weeks
|
Change in maternal aspartate aminotransferase (AST) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Gamma-Glutamyl Transferase (GGT) Levels
Tidsramme: Baseline, 6 weeks
|
Change in maternal gamma-glutamyl transferase (GGT) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Symptom Checklist-90-Revised (SCL-90-R) scale
Tidsramme: Baseline, 3 weeks
|
The SCL-90-R is a 90-item self-report questionnaire assessing psychological symptoms over the past week, with a range of 0-90 across 9 dimenions: Somatization, Obsessive-compulsive, Interpersonal sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation, Psychoticism. Higher scores indicate worse outcome. |
Baseline, 3 weeks
|
|
Change in infant BMI z-score
Tidsramme: Baseline, 6 weeks
|
We will measure infant body weight, length, and head circumference to calculate BMI z-scores according to WHO growth standards, and changes between baseline, 6 weeks and 4 months will be assessed. |
Baseline, 6 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maternal and infant gut microbiome composition
Tidsramme: Baseline, 6 weeks
|
Bacterial DNA will be isolated from infant and maternal fecal samples and sequenced to obtain microbiome composition. |
Baseline, 6 weeks
|
|
Maternal plasma and breast milk metabolomic profile
Tidsramme: Baselina, 6 weeks
|
The metabolomic profile will be obtained with the Biocrates Quant 1000 kit from plasma and breast milk samples. |
Baselina, 6 weeks
|
|
Milk imprinted protein levels
Tidsramme: Baseline, 6 weeks
|
Imprinted proteins in human milk samples will be analyzed by ELISA. |
Baseline, 6 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Carles Lerin, PhD, Fundació Sant Joan de Déu
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- PIC-143-25
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .